Accessibility helpSkip to navigationSkip to contentSkip to footer
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign In
  • Home
  • World
    Sections
    • World Home
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • China demands schoolteachers hand in their passports
    • Trump would raise US debt by twice as much as Harris, report finds
    • Starmer wields the knife after shaky first 100 days
    • Ireland slams Israel’s ‘outrageous’ demands to its peacekeepers
    • EY to hold back some pay from US partners after tough year
  • US
    Sections
    • US Home
    • US Economy
    • Investing in America
    • US Companies
    • US Politics & Policy
    • US Presidential Election 2024
    Most Read
    • Trump would raise US debt by twice as much as Harris, report finds
    • EY to hold back some pay from US partners after tough year
    • The perils of America’s chips strategy
    • Anxious Europeans hoard savings as US consumers boost global economy
    • The swing state battles that will win the US election
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • How Jane Street rode the ETF wave to ‘obscene’ riches
    • EY to hold back some pay from US partners after tough year
    • Why private credit’s gung-ho growth needs proper monitoring
    • BBC and other public UK broadcasters strike Amazon streaming service deal
    • Richemont to sell struggling Yoox Net-a-Porter to Mytheresa
  • Tech
    Sections
    • Tech Home
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
    Most Read
    • The perils of America’s chips strategy
    • Why tech unicorns struggle to avoid the glue factory
    • OpenAI is right to abandon non-profit status
    • US funding drives investment for European military tech start-ups
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
    Most Read
    • Trump would raise US debt by twice as much as Harris, report finds
    • How Jane Street rode the ETF wave to ‘obscene’ riches
    • Spain to propose mini-coalitions to break EU capital markets stalemate
    • Why private credit’s gung-ho growth needs proper monitoring
    • Southern Water seeks to borrow nearly £4bn from investors
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Why private credit’s gung-ho growth needs proper monitoring
    • How I learnt to stop worrying and (mostly) love the e-bike
    • The perils of America’s chips strategy
    • Leaving stuff on the stairs to take up later is not OK
    • Make sure you are buying the dip not the freefall
  • Lex
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
    Most Read
    • How I learnt to stop worrying and (mostly) love the e-bike
    • Make sure you are buying the dip not the freefall
    • The case for office pettiness
    • The unusual perks of London’s oldest members’ club
    • Why tech unicorns struggle to avoid the glue factory
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • How I learnt to stop worrying and (mostly) love the e-bike
    • Leaving stuff on the stairs to take up later is not OK
    • In a world of SUVs, the compact jeep is king
    • The unusual perks of London’s oldest members’ club
    • Regeneron head says weight-loss drugs could cause ‘more harm than good’
  • HTSI
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Lex
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Medical science

  • Wednesday, 2 October, 2024
    Science
    Map of adult insect’s brain offers clues on neurological diseases

    International collaboration plotted 149 metres of biological wiring in fruit fly

    Caption: The fruit fly connectome contains a wide range of information, from cell types and synapses to neurotransmitters and network properties. Here, cells are color-coded by their defining chemical messenger. Blue: GABA; yellow: acetylcholine (ACH); pink: glutamate (GLUT).
  • Wednesday, 2 October, 2024
    Artificial intelligence
    DeepMind and BioNTech build AI lab assistants for scientific research

    Artificial intelligence used to help researchers plan experiments and better predict outcomes

    Montage of Google DeepMind and BioNTech logos with a finger on a smartphone in the foreground and semiconductor chip design in the background
  • Monday, 30 September, 2024
    Roche Holding AG
    Roche plans to launch drugs and slash development costs

    Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer

    A Roche Research laboratory
  • Friday, 27 September, 2024
    FT Magazine
    Inside the ‘killer cell’ factory

    The next stage in the war on cancer may be enlisting patients’ own blood cells to fight the disease

    Two men dressed in business suits standing side by side under a tree
  • Thursday, 26 September, 2024
    Anthony McDonnell
    Antimicrobial resistance is dangerous in more ways than one

    The reduced effectiveness of antibiotics risks severe disruption to the global economy

    Staff members work on the production line of penicillin antibiotics
  • Tuesday, 17 September, 2024
    Drugs research
    AstraZeneca and MSD hail progress in tackling hard-to-treat cancers

    Results offer hope of progress in combating bladder tumours and some forms of breast cancer

    Doctor examines mammogram of breast
  • Saturday, 14 September, 2024
    FT Magazine
    Storytelling with the pioneer of ‘narrative medicine’

    Rita Charon believes that letting patients tell their own stories is the best way to fix a broken system

    Rita Charon standing beside a wall filled with shelves of books and floor lamp
  • Thursday, 12 September, 2024
    Special ReportFT Health: Communicable Diseases
    Bird flu and mpox show little learnt from Covid about future pandemics

    More aggressive actions and better co-ordinated responses needed to contain viruses, say public health experts

    Several workers dressed in white protective coveralls are attending to rows of chickens inside a poultry farm
  • Thursday, 12 September, 2024
    Thomas Frieden
    We must strengthen public health surveillance to stop disease outbreaks

    Flying blind is dangerous. Technology can build on the basics of local and national data collection

    An individual wearing a white protective lab coat, gloves, and glasses is opening what seems to be a cryogenic tank
  • Thursday, 12 September, 2024
    Special ReportFT Health: Communicable Diseases
    Public health in global south faces vaccine cold storage challenge

    Issue hampers effort to exploit mRNA technology’s promise in tackling deadly viral outbreaks

    A female healthcare worker prepares a vaccine. Behind her in a chair is a woman and her baby
  • Thursday, 12 September, 2024
    Special ReportFT Health: Communicable Diseases
    Book review: surveying the four decades since Aids

    CDC officials recount the critical role of politicians and others surrounding the story of HIV

  • Thursday, 12 September, 2024
    Special ReportFT Health: Communicable Diseases
    Inadequate diagnostics increase chances of another pandemic

    Early warning system requires roll out of latest testing techniques, Covid levels of co-operation and greater regulatory harmonisation

    a group of people wearing protective gear working in a large room, likely a testing or medical setup
  • Wednesday, 11 September, 2024
    Virtual and Augmented Reality
    UK pioneers synthetic touch technology with scope to transform healthcare

    UCL unveils new sensory device that will help doctors to spot disease early and advance robotic surgery

    Sara Adela Abad demonstrating the synthetic touch technology
  • Wednesday, 4 September, 2024
    Anjana Ahuja
    Molecular ‘de-extinction’ sparks the imagination

    Scientists’ goal is not to resurrect vanished creatures but discover whether ancient molecules can solve modern problems

    Andy Carter illustration of a zombie hand made of molecules reaching out from a petri dish filled with molecules, proteins and DNA.
  • Thursday, 29 August, 2024
    Drugs research
    The cost of cracking cancer

    A three-part FT series looks at how an influx of money is changing prospects for patients but creating new challenges for healthcare systems

  • Thursday, 29 August, 2024
    The cost of cracking cancer
    The Covid-era tech that could reinvent cancer care

    Pandemic winners BioNTech and Moderna face hurdles as they seek to bring their groundbreaking technology to oncology

  • Wednesday, 28 August, 2024
    Dementia
    Patients on diabetes drugs less likely to develop dementia, research finds

    More trials urged as part of effort to slow cognitive declines with existing medicines

    A woman with diabetes monitors her blood glucose level
  • Wednesday, 28 August, 2024
    The FT ViewThe editorial board
    The disappointing international response to mpox

    Wealthy world must help Africa prevent a potential regional health catastrophe

    Elisabeth Furaha applies medication on the skin of her child Sagesse Hakizimana who is under treatment for Mpox
  • Wednesday, 28 August, 2024
    John Hardy
    The disappointing Alzheimer’s decision is part of a bigger problem

    Nice’s ruling on lecanemab demonstrates the lack of readiness to roll out new treatments in the UK

    Alzheimer’s Drug lecanemab / Leqembi
  • Tuesday, 27 August, 2024
    The cost of cracking cancer
    The cost of cracking cancer: what the $1tn race for a cure leaves behind

    The first in an FT series looking at the new energy behind the fight for cancer cures

    A montage showing a scientist wearing protective gear, including a hairnet, mask, and gloves, handling a syringe. To the right, a petri dish with nematodes visible inside. The background features an image of pancreatic cancer cells.
  • Sunday, 25 August, 2024
    InterviewMpox
    Mpox surveillance must be improved to tackle Africa surge, expert warns

    Infectious disease professor Dimie Ogoina says cases are probably being under-reported

    Health workers in blue protective gowns and face masks discuss treatment with a man and a child at the Munigi mpox treatment center in Nyiragongo territory, North Kivu, Democratic Republic of Congo. The man, wearing a striped shirt, sits on a bed with a black backpack beside him, and the child sits nearby wearing a pink shirt. Both patients have bandages on their arms.
  • Friday, 23 August, 2024
    Disease control and prevention
    Cancer care waiting times triple in England since 2012

    Third of patients wait longer than 62-day standard to start treatment, according to ONS data

    Chemotherapy being administered
  • Wednesday, 21 August, 2024
    Disease control and prevention
    Wider use of antibiotic would reduce child mortality in Africa, study finds

    WHO reviews Niger trial as issue highlights dilemma over threat of ‘superbugs’

    A nurse examines a child in the village of Dan-Mazadou in southeastern Niger
  • Monday, 19 August, 2024
    Neurotechnology
    Implants reduce Parkinson’s symptoms by reading brain activity

    Computer interface technology promises a ‘smart pacemaker’ to help sufferers of the motor disease

    Computer scan of Parkinson’s patient brain
  • Friday, 16 August, 2024
    ExplainerMpox
    How dangerous is the mpox public health emergency?

    Authorities are rushing to contain latest outbreak fuelled by a more dangerous type of the virus

    Boy suffering from Mpox in Democratic Republic of Congo July 19, 2024. plus Mpox virus particles in background
Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency Converter

Community & Events

FT Live EventsFT ForumsBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2024. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Edition:International
UK
Subscribe for full access

Top sections

  • Home
  • World
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
  • US
    • US Economy
    • Investing in America
    • US Companies
    • US Politics & Policy
    • US Presidential Election 2024
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
  • Markets
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Lex
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Alphaville
  • FT Edit
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Schools
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • FT Digital Edition
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In